Grace Therapeutics secures $4.0M from warrant exercise; GTx-104 PDUFA date set for April 23, 2026

Grace Therapeutics, Inc.

Secured $4.0M via exercise of 1,345,464 common warrants at $3.003/share from September 2023 private placement.
Remaining 1,190,927 warrants from the same placement expired after FDA accepted GTx-104 NDA for review.
FDA set PDUFA target date of April 23, 2026 for GTx-104 NDA for aneurysmal subarachnoid hemorrhage (aSAH).
GTx-104 is a novel injectable nimodipine formulation for I.V. infusion in aSAH patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.